Recent trial studies have shown that omega-3 supplementation can beneficially improve
scores on the Expanded Disability Status Scale (EDSS), which is considered a gold standard for measuring
disability and disease severity in Multiple Sclerosis (MS) patients, as well as reducing neuroinflammation.
The present systematic review and meta-analysis aimed to evaluate the effect of omega-3
supplementation on EDSS and cytokines in MS. A systematic search was performed on Pubmed, Scopus
and Cochrane Library up to October 2018. Studies were reviewed based on the Cochrane handbook,
and the preferred reporting items for systematic reviews and meta-analyses (PRISMA).
Weighted Mean Difference (WMD) with 95% Confidence Intervals (CI) were pooled using a random
effects model in order to compare the effects of omega-3 with placebos. Among 4 trials, omega-3 supplementation
had no significant effect on EDSS scale (WMD: -0.07; 95% CI: -0.27 to 0.13; P=0.50),
as well as serum levels of IL-1β (WMD: -7.67; 95% CI: -23.31 to 7.97; P=0.34) and IL-6 (WMD:
-153.57; 95% CI: -455.36 to 148.23; P=0.32). However, omega-3 significantly reduced TNF-α concentration
(WMD: -16.76; 95% CI: -18.63 to -14.88; P < 0.00001) compared to placebo. Overall,
omega-3 supplementation may not have a clinically considerable impact on EDSS or proinflammatory
markers. However, the existing trials are limited in this context, and further clinical trials are required
to confirm the potential effects of the omega-3 supplement on MS disease management.